Bayer to divest animal health business to Elanco for $7.6bn

US-based veterinary pharmaceuticals producer Elanco Animal Health has agreed to acquire German drug giant Bayer’s animal health business for $7.6 billion, financed by a combination of 70% cash and 30% equity.

The transaction, which enhances emerging market presence and strengthens cattle business, will strengthen Elanco’s Innovation, Portfolio, and Productivity (IPP) strategy, creating the second largest veterinary-medicine company by global revenue.

Elanco is expected to double pet business with well-known brands by balancing its Food Animal and Companion Animal segments and integrate veterinary focus with Bayer’s e-commerce and retail leadership for full channel coverage.

Under the deal, the company will expand innovation through pipeline, delivery platforms, scale and certain access rights to Bayer’s CropScience R&D pipeline and de-prioritized clinical pharma assets.

Bayer to sell animal health business to Elanco

Bayer to sell animal health business to Elanco. Photo courtesy of Bayer AG.

Jeffrey N Simmons – president and CEO of Elanco said:  “In our first four quarters as an independent company, we have validated the significant value creation potential from a dedicated focus on animal health and a targeted strategy.

See also  Lupin gains FDA nod for generic Diflucan Tablets production

“Joining Elanco and Bayer Animal Health strengthens and accelerates our IPP strategy, transforms our portfolio with the addition of well-known pet brands, brings an increased presence in key emerging markets, expands innovation, and accelerates our margin expansion journey.

“The move combines our long-standing focus on the veterinarian while meeting pet owners’ changing expectation of pet care and access to products.”

Apart from adjusted gross margin goals and double-digit adjusted earnings before interest, tax, depreciation, and amortization (EBITDA) margin growth, Elanco expects the combined organization to deliver mid-single-digit revenue growth.

See also  Strides Pharma gets FDA nod for Mycophenolate Mofetil, targets $145m market

Werner Baumann – CEO of Bayer said: “Our Animal Health business is among the pioneers of this sector, having built up an attractive portfolio and secured well-established market positions in the companion and farm animal segments.

“And now, the combination with Elanco will give rise to a leading competitor in the animal health industry, benefiting customers, employees and shareholders alike.”

Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close in mid-2020.

Related posts

See also  Mylan launches generic Estradiol Vaginal Cream after securing FDA approval

The post Bayer to divest animal health business to Elanco for $7.6bn appeared first on PharmaNewsDaily.com.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.